• Biotricity’s board and consenting shareholders executed a joint written consent dated May 28, 2026 to move ahead with a reverse stock split.
• The action authorizes a 100-for-1 reverse split of issued and outstanding common stock, targeted for implementation within 10 days of FINRA notice.
• Fractional shares will be rounded up to the nearest whole share, with no cash paid for fractional interests.
• The board retained discretion to abandon the reverse split if it later determines the transaction is no longer in shareholders’ best interests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028773), on June 16, 2026, and is solely responsible for the information contained therein.